Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.32 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.32 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 4/20 | 0.31 |
| ▸ | CA2 | P00918 | 4/20 | 0.31 |
| ▸ | CA9 | Q16790 | 4/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
| ▸ | VCP | P55072 | 1/20 | 0.30 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12652025 | 0.91 | MAPK1 (0.34) | MAPK1PTGS2NTRK1IKBKETBK1 | |
| SCHEMBL12652027 | 0.91 | PTGS2 (0.34) | PTGS2NTRK1IKBKETBK1CA1 | |
| SCHEMBL12651820 | 0.89 | CA1 (0.43) | PTGS2IKBKETBK1CA1CA2 | |
| SCHEMBL1791780 | 0.87 | PTGS2 (0.38) | PTGS2NTRK1CA2CA9ADORA2A | |
| SCHEMBL1792358 | 0.85 | NTRK1 (0.31) | NTRK1 | |
| SCHEMBL1790384 | 0.84 | NTRK1 (0.35) | MAPK1PTGS2NTRK1PTK2 | |
| SCHEMBL1792271 | 0.81 | PTGS2 (0.34) | MAPK1PTGS2NTRK1PTK2 | |
| SCHEMBL1792081 | 0.80 | TP53 (0.39) | MAPK1PTGS2NTRK1CA1CA2 | |
| SCHEMBL1789966 | 0.80 | PTGS2 (0.39) | PTGS2ADORA2AMAPT | |
| SCHEMBL1789942 | 0.80 | PTGS2 (0.39) | PTGS2CA1CA2CA9ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, CYP2S1, DPYD | MAPK1 2045/4885PTGS2 491/4885NTRK1 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.